PDCD1 and small cell lung carcinoma: At present, at least four phase 3 randomized clinical trials have shown statistically significant overall survival improvement with the addition of different anti-PD1 or anti-PD-L1 agents to the standard chemotherapy as the first-line treatment for ES-SCLC: Impower 133, ASTRUM, CAPSTONE, CASPIAN (4–7).